VIMTALABSNSEVimta Labs Limited· PharmaceuticalsLowNeutral
Announced Fri, 6 Jun · 23:15 IST

Vimta Labs Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on Jun 06, 2025. Further, the company has informed the Exchange regarding voting results.

Board & Shareholder Meetings View source PDF

VIMTALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Vimta Labs Limited held its 35th Annual General Meeting on June 6, 2025, via video conferencing, where all 13 resolutions were passed. Key approvals include the adoption of audited financial statements for FY ended March 31, 2025, and the declaration of a dividend of Rs. 2 per equity share. Shareholders also approved the issue of bonus shares and the re-appointment of directors, including Dr. Yadagiri R Pendri as Independent Director. Special resolutions to increase the company's overall borrowing limits and limits for disposal/encumbrance of company undertakings passed with 92.19% approval, while revision of remuneration for the Managing Director and two Executive Directors was also approved. Total shareholder participation was approximately 38.34% of outstanding shares, with promoters voting at 92.77%.

Likely market impact

The approval of a Rs. 2 per share dividend and bonus share issue is positive for shareholders, signaling confidence in the company's performance. The increase in borrowing limits and the addition of new objects in the MoA provide management with greater financial and operational flexibility for future growth.